Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis

Therapuetic Areas:Cardiology / Vascular Diseases
Age Range:Any
Start Date:April 2006
End Date:April 2019

Use our guide to learn which trials are right for you!

Determining Disease Activity Biomarkers in Individuals With Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis

Granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA) are two
rare immune system disorders that cause the inflammation of blood vessels, or vasculitis. In
order to properly treat these diseases, it is critical that the level of disease activity can
be determined over the course of the disease. The purpose of this study is to determine new
biological markers, or biomarkers, that may be used to assess the severity of disease in
people with GPA or MPA.

GPA and MPA are two autoimmune disorders that cause systemic vasculitis. GPA commonly affects
the upper respiratory tract, the lungs, and the kidneys. MPA is marked by kidney
inflammation, weight loss, skin lesions, nerve damage, and fever. Many patients with WG or
MPA show no visible symptoms of active disease; it is known that underlying subclinical
disease activity leads to long-term damage in these patients. Also, because it is difficult
to monitor WG and MPA disease activity, it is difficult for clinicians to know when and how
to treat these patients. This study will use new scientific methods to identify new
biomarkers that can be used to monitor disease activity in GPA and MPA patients. These
biomarkers may be used to help direct clinical care for GPA and MPA patients and assist in
future drug development.

Study visits will occur monthly for the first year, then every 3 months thereafter for the
remainder of the study. Blood and urine collection will occur at every visit. A physical exam
and medical and medication history will occur every 3 months; also, participants will be
asked to complete several questionnaires to assess disease activity, health status, and
tobacco, alcohol, and drug use. Participants may have additional study visits if a disease
flare or disease-related complications occur during the study.

Inclusion Criteria:

- Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to
classification criteria or definitions, have not been developed for GPA and MPA.

- For diagnosis of GPA, meets at least 2 of the following 5 modified American College of
Rheumatology (ACR) criteria:

1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood

2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities

3. Urinary sediment with microhematuria or red cell casts

4. Granulomatous inflammation within the wall of an artery or in the perivascular
area on biopsy

5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for
either PR3- or MPO-ANCA

- For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:

1. Necrotizing vasculitis, with few or no immune deposits, that affects small
vessels (i.e., capillaries, venules, arterioles)

2. Necrotizing arteritis involving small- and medium-sized arteries may be present

3. Necrotizing glomerulonephritis is very common

4. Pulmonary capillaritis often occurs

- Parent or guardian willing to provide informed consent, if applicable

Exclusion Criteria:

- Simultaneous diagnoses of both GPA and MPA

- Granulomatosis with polyangiitis (Churg-Strauss)

- Takayasu's arteritis

- Giant cell arteritis

- Polyarteritis nodosa

- Cogan's syndrome

- Behcet's disease

- Sarcoidosis

- Kawasaki disease

- Tuberculosis or any atypical mycobacterial infections

- Deep fungal infections

- Lymphoma, lymphomatoid granulomatosis, or any other type of cancer that mimics
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAVs)

- Cryoglobulinemic vasculitis

- Systemic lupus erythematosus

- Rheumatoid arthritis

- Mixed connective tissue disease or any overlapping autoimmune syndrome
We found this trial at
72 East Concord Street
Boston, Massachusetts 02118
(617) 638-5300
Principal Investigator: Paul A. Monach, MD, PhD
Phone: 617-414-2512
Boston University School of Medicine A leader in medical education and research, Boston University School...
Boston, MA
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
Principal Investigator: Larry Moreland, MD
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
Pittsburgh, PA
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Curry Koening, MD, MHS
Phone: 801-585-0798
University of Utah Research is a major component in the life of the U benefiting...
Salt Lake City, UT
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Carol A. Langford, MD, MHS
Phone: 216-445-1397
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Cleveland, OH
Click here to add this to my saved trials
Hamilton, Ontario
Principal Investigator: Nader A. Khalidi, MD
Phone: 905-522-1155
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Peter Merkel, MD, MPH
Phone: 215-614-4407
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Ulrich Specks, MD
Rochester, MN
Click here to add this to my saved trials